Clinical trials: Small Cell Cancer Of The Lung
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
Primary Objective: Safety run-in part: to assess the tolerability and to determine the recommended doses of tusamitamab ravtansine in combination with pembrolizumab and tusamitamab ravtansine in combination with pembrolizumab and…
- Trial name
- CARMEN-LC05 (NCT04524689)
- Testing
- SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin
- Where
- 22 sites in United States, Brazil and 6 more
- Volunteers
- 57 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Clinical Trial in Chinese Healthy Volunteers of GB222
The primary objective of this study is to evaluate the similarity of the primary pharmacokinetic (PK) parameter AUC0-t of GB222 and bevacizumab after single administration; the secondary objective is to observe the safety and…
- Trial name
- NCT04175158
- Testing
- GB222, Bevacizumab
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Genor Biopharma Co., Ltd.
Non Small Cell Lung Cancer, Small-cell Lung Cancer
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side…
- Trial name
- NCT04022876
- Testing
- ALRN-6924, Carboplatin, Pemetrexed
- Where
- 28 sites in United States, Bosnia and Herzegovina and 5 more
- Volunteers
- 35 people
- Sponsor
- Aileron Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after…
- Trial name
- LUX-Lung-IO (NCT03157089)
- Testing
- Afatinib, pembrolizumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern…
- Trial name
- NCT00085839
- Testing
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- OSI Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the neoadjuvant therapy efficacy of IBI110 in combination with sintilimab versus sintilimab alone based on pathologic complete response (pCR) rate in stage IIB (primary tumor > 4 cm )…
- Trial name
- NCT05088967
- Testing
- IBI110, sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or…
- Trial name
- NCT01604863
- Testing
- HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Recurrent Non Small Cell Lung Cancer
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
This study will compare the anti-tumor efficacy of apricoxib and erlotinib with placebo and erlotinib as measured by time to disease progression to test the hypothesis that down regulation of COX-2 and EGFR pathways in patients…
- Trial name
- TP2001-201 (NCT00652340)
- Testing
- apricoxib/erlotinib
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
- Trial name
- NCT00434174
- Testing
- Everolimus, Pemetrexed
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency
The purpose of this study is to determine whether Icotinib is efficient and safe in treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.
- Trial name
- NCT02062515
- Testing
- icotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
The purpose of this study is to compare 3years of disease-free survival (DFS) of Icotinib and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.
- Trial name
- ICWIP (NCT02125240)
- Testing
- Icotinib
- Where
- 11 sites in China
- Volunteers
- 124 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non Small Cell Lung Cancer Metastatic
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC
This is a randomized, multicenter, multinational, double-blind, and parallel-group study to evaluate the PK, efficacy, safety and immunogenicity of MB12 (proposed pembrolizumab biosimilar) versus Keytruda® in subjects with newly…
- Trial name
- NCT05668650
- Testing
- Pembrolizumab, Pembrolizumab biosimilar
- Where
- Argentina
- Volunteers
- 174 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Non-Small Cell Lung Cancer, Lung Cancer
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation…
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
- Trial name
- NCT06685718
- Testing
- BG-60366
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 33 people
- Sponsor
- BeOne Medicines
Cancer
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT00630110
- Testing
- docetaxel, NPI-2358 + docetaxel
- Where
- 36 sites in United States, Argentina and 4 more
- Volunteers
- 172 people
- Sponsor
- Nereus Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC)
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1…
- Trial name
- NCT04139317
- Testing
- Capmatinib, Pembrolizumab
- Where
- 36 sites in Australia, Belgium and 14 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer, Nonsmall Cell Lung Cancer
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
- Trial name
- NCT04396340
- Testing
- XMT-1592
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics
Carcinoma, Non-Small Cell Lung
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
- Trial name
- NCT00300885
- Testing
- Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel, Carboplatin plus Paclitaxel
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 926 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.